Holen Sie sich die Stockscreener-App
2.43
13.02%
0.28
Schlusskurs vom Vortag:
$2.15
Offen:
$2.17
24-Stunden-Volumen:
339.09K
Relative Volume:
0.50
Marktkapitalisierung:
$61.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.24M
KGV:
-2.9001
EPS:
-0.8379
Netto-Cashflow:
$-22.47M
1W Leistung:
+22.73%
1M Leistung:
+31.00%
6M Leistung:
-34.68%
1J Leistung:
-78.53%
1-Tages-Spanne:
$2.17
$2.48
1-Wochen-Bereich:
$1.99
$2.48
52-Wochen-Spanne:
$1.14
$11.20
Skye Bioscience Inc Stock (SKYE) Company Profile
Firmenname
Skye Bioscience Inc
Sektor
Branche
Telefon
(858) 410-0266
Adresse
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Vergleichen Sie SKYE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.40 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1495 | 337.87M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
2.79 | 118.85M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
1.00 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
40.56 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-09-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Purchased by Deutsche Bank AG - Defense World
Deutsche Bank AG Purchases 32,054 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (NASDAQ:SKYE) Shares Up 24%Still a Buy? - MarketBeat
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by BNP Paribas Financial Markets - Defense World
BNP Paribas Financial Markets Has $90,000 Stock Holdings in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Northern Trust Corp Sells 5,170 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by Northern Trust Corp - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Up 24% – Should You Buy? - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Up 24% – Here’s What Happened - Defense World
Skye Bioscience’s SWOT analysis: obesity drug stock poised for pivotal data - Investing.com Nigeria
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $923,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Zacks Investment Research
Arecor CEO on Skye Bioscience partnership and the value of collaborations - Proactive financial news
Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewswire
Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewswire Inc.
Skye Bioscience’s (SKYE) Outperform Rating Reiterated at William Blair - Defense World
Skye Bioscience (NASDAQ:SKYE) Earns Outperform Rating from William Blair - Defense World
Ensign Peak Advisors Inc Has $2.17 Million Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Protagenic and Phytanix merger prompts a stock surge - BioWorld MedTech
Skye Bioscience Establishes Partnership with Arecor Therapeutics - GuruFocus
Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews
Arecor shares jump 10% on obesity drug partnership with Skye Bioscience - Proactive financial news
Arecor partners with Skye Bioscience to improve formulation of obesity drug - Proactive financial news
Skye Bioscience Partners with Arecor Therapeutics to Enhance Nimacimab Formulation for Obesity Treatment - Nasdaq
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab - The Manila Times
Skye Bioscience Establishes Partnership with Arecor - GlobeNewswire
New Obesity Drug Breakthrough: Skye Bioscience's Once-Weekly Treatment Gets Powerful Upgrade - Stock Titan
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Consensus PT from Analysts - Defense World
Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Target Price at $16.60 - Defense World
Skye Bioscience Awards 100,000 Share Options at $1.82 with 4-Year Vesting Terms - Stock Titan
Skye Bioscience (SKYE) Reveals Key Findings on CB1 Inhibitors an - GuruFocus
Skye Bioscience Clinical Model Demonstrating Necessity of - GlobeNewswire
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - Stock Titan
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Bought by Barclays PLC - Defense World
Barclays PLC Has $198,000 Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (SKYE) Receives Adjusted Price Target from Oppen - GuruFocus
Oppenheimer cuts Skye Bioscience price target to $17 By Investing.com - Investing.com South Africa
Oppenheimer cuts Skye Bioscience price target to $17 - Investing.com
Braidwell LP Invests $2.34 Million in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE) - ACCESS Newswire
Finanzdaten der Skye Bioscience Inc-Aktie (SKYE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Skye Bioscience Inc-Aktie (SKYE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
| Grayson Paul A. | Director |
Nov 15 '24 |
Sale |
5.55 |
307 |
1,704 |
345,945 |
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):